Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
November 6, 2015 12:00 PM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.
Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More
Acadia Pharma (ACAD) Tops Q3 EPS by 1c
November 5, 2015 4:13 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More